Pharmaceutical CDMO Market to Reach US$ 270.3 Bn by 2031, Growing at 7.2% CAGR, New Report by Wissen Research

Wissen Research forecasts the global pharmaceutical CDMO market will expand from $191.0 billion in 2026 to $270.3 billion by 2031, a 7.2% CAGR. Growth is expected to be driven by rising outsourcing, demand for biologics, cell and gene therapies, ADCs and mRNA medicines, and investment in automation, single-use systems and AI-based process optimization. North America remains the largest market, while Asia-Pacific—particularly China—is projected to be the fastest-growing region as major CDMOs expand specialized biologics and advanced-therapy capacity.

Analysis

This is not independently validated demand data and should not move estimates by itself. The investable issue is whether utilization improves fast enough to absorb the biologics, sterile-fill-finish and advanced-therapy capacity added since 2022; absent that, nominal market growth can coexist with price competition and subpar returns on invested capital. LONN has the cleanest operating leverage to an upswing in outsourced large-molecule commercialization, while TMO has a more diversified, lower-beta exposure through its pharma-services and workflow franchise.

The likely near-term bottleneck is not broad CDMO capacity but qualified capacity in high-potency APIs, aseptic fill-finish and validated late-stage biologics processes. That favors incumbents with established regulatory inspection histories and customer switching costs, but also raises execution risk: a single warning letter, batch failure, or delayed customer approval can impair an asset’s utilization for multiple quarters. CRL is less direct exposure to commercial manufacturing and should not receive the same multiple benefit; its upside depends more on preclinical/early-development activity translating into client funding and program starts.

Over 6-18 months, the underappreciated competitive pressure is Chinese capacity: it can compress commodity API and discovery-service pricing even if global volumes rise. Western sponsors’ China-risk diversification supports premium capacity outside China, but only where customers value regulatory redundancy enough to pay for it. For ABBV, MRK and PFE, greater outsourcing is principally a capital-efficiency lever rather than a material standalone earnings catalyst; the larger read-through is to pipeline throughput and launch reliability.

Consensus may be too quick to extrapolate advanced-therapy demand into broad CDMO earnings. Cell/gene therapy remains a volatile, low-utilization category, and biotechs continue to prioritize cash preservation; commercial biologics utilization and booked backlog conversion—not announced capacity—should determine relative performance. Falsify a constructive LONN/TMO view if quarterly utilization, bioprocess order growth, or 2027 margin guidance fail to improve despite reported pipeline growth.

Key Decisions for Investors

• No event-driven trade on the research release alone; set an alert for LONN quarterly bookings, utilization and 2027 margin commentary. Initiate/expand only after evidence of commercial biologics backlog conversion, targeting 12-18 months and limiting thesis risk to a guidance cut or renewed pricing pressure.
• Prefer a 6-12 month long LONN / short CRL pair for investors seeking CDMO exposure: LONN has more direct late-stage biologics and commercial-manufacturing operating leverage, while CRL remains more exposed to funding-sensitive early-stage biotech activity. Exit if CRL’s client demand indicators accelerate materially faster than LONN’s commercial backlog.
• Maintain TMO as the lower-volatility expression rather than chase pure-play capacity builders. Add on weakness following a confirmed improvement in Pharma Services organic growth; risk/reward is less asymmetric than LONN but diversified instruments and consumables cushion a delayed CDMO recovery.
• Avoid using ABBV, MRK or PFE as direct outsourcing-growth proxies. Reassess only around launch-readiness disclosures for major biologic pipelines, where external manufacturing constraints could affect revenue timing rather than sector-level CDMO forecasts.